BGNE241220P155000
- 0.60
- 0.000.00%
BeiGene Newsroom
Institutions reiterated a "Buy" rating for BEIGENE (06160), being bullish on its strong oncology drug research and development pipeline.
Recently, BEIGENE (06160) held an investor conference call to introduce important data presentations at the USA Hematology Association (ASH) and the San Antonio Breast Cancer Symposium (SABCS). Subsequently, TD Cowen Inc 7.75% Senior Notes Due 15/06/33 Usd25 reaffirmed BEIGENE's "Buy" rating and maintained a Target Price of $260.00, which aligns with the consensus of many Analysts who believe that this Stocks has potential for upward movement.
Bank of America Merrill Lynch has lowered the Target Price for Shanghai Pharmaceuticals (01093.HK) to 4.6 yuan and raised the Target Price for INNOVENT BIO (01801.HK) to 56.4 yuan.
Merrill Lynch Securities released a Research Report stating that CSPC PHARMA (01093.HK) and BEIGENE (06160.HK) have reached a global exclusive licensing agreement for the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor SYH2039 and subsequent development. Taking into account the aforementioned collaboration and the recent bidding results of the tenth batch of national organization pharmaceutical centralized procurement, the revenue forecasts for CSPC PHARMA for 2024 to 2026 have been adjusted down by 0.8%, up by 1.7%, and down by 1.7%, respectively, while the earnings per share forecasts have been adjusted down by 0.9%, up by 10.5%, and down by 1.9%. Considering CSPC PHARMA's core product Enbrel.
UBS Group: The price reduction of the tenth round of collective procurement of Pharmaceuticals exceeded expectations, showing a cautious attitude towards the China generic drug market.
UBS Group released a research report stating that the tenth batch of national Pharmaceutical procurement in the mainland involves 62 types of Pharmaceuticals, with 385 products eligible for selection. Although the government has not disclosed the price reduction situation, according to Statistics, this time the reduction exceeds expectations, reaching 80% to 96%, and it is believed to be the largest reduction in history. The results of the Pharmaceutical procurement will be comprehensively implemented nationwide starting from April next year and will remain effective until the end of 2027. Overall, UBS Group believes that the results of the tenth batch of national Pharmaceutical procurement reflect China's tightening of the basic Medical Insurance Fund, and the government has also increased support for new drugs. Looking ahead, the bank holds a cautious attitude towards the prospects of China's generic drug market, and also anticipates.
US stocks movement | BEIGENE continues to rise 0.84% in pre-market trading with several Institutions giving it a Buy rating.
Gelonghui, December 18 | Yesterday, BEIGENE (BGNE.US) closed up 1.55%, and in Pre-Market Trading today, it continued to rise by 0.84%, reaching $180.56. Analyst Kelly Shi from Jefferies Group maintains a Buy rating for BEIGENE and keeps the Target Price at $286. TD Cowen Inc 7.75% Senior Notes Due 15/06/33 Usd25 analyst Yaron Werber also maintains a Buy rating for BEIGENE with a Target Price of $260. (Gelonghui)
Quick look at the Hong Kong market | All three major Indices closed higher, the Science and Technology Index rose nearly 2%; technology, Autos, and Biotechnology stocks climbed, with Li Auto rising over 5%, and Xiaomi Group and WUXI BIO rising nearly 3%.
Many Network Technology stocks are rising, XIAOMI-W is up 2.84%, Baidu Group-SW is up 1.74%; Semiconductor stocks are all rising, HG SEMI is up 7.64%, BEKE is down 2.78%; Autos stocks are climbing, LEAPMOTOR is up 6.42%, BRILLIANCE CHI is up 6.29%;
Express News | The USA Biological Security Act was not included in the CR bill.
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $260
BeiGene (BGNE) Gets a Buy From TD Cowen
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
BeiGene: Promising Growth Trajectory and Investment Opportunity Backed by Strong Product Pipeline and Robust Financials
Express News | According to the Hong Kong Stock Exchange: On December 11, JPMorgan's short position in BEIGENE decreased from 2.42% to 1.66%.
BEIGENE issued 1.3 million shares due to the exercise of stock options.
BEIGENE (06160) announced that 1.3 million shares will be issued due to a Director exercising stock options on December 14, 2024.
BEIGENE (06160.HK) issued 1.3 million shares due to the exercise of stock options.
Gelonghui reported on December 16 that BEIGENE (06160.HK) announced the issuance of 1.3 million ordinary shares due to a Director exercising stock options on December 14, 2024.
Super Micro Computer, Adobe And Nucor Are Among Top Large Cap Losers Last Week (December 9-13): Are The Others In Your Portfolio?
This week's Hong Kong stock bull | The "first domestic makeup stock" in Hong Kong! Mao Ge Ping soared over 86% in its first week of listing; Consumer encouragement policies are expected to continue to strengthen, and Lao Pu Gold has increased by over 20%.
This week, the Hang Seng Index increased by 0.53%, closing at 19,971.24 points; during the same period, the Hang Seng TECH Index rose by 0.33%, closing at 4,479.6 points; the Hang Seng China Enterprises Index increased by 0.7%, closing at 7,186.59 points.
Sector Update: Health Care Stocks Steady Premarket Friday
Sector Update: Health Care
CSPC Pharmaceutical Group Grants Exclusive License of Cancer Inhibitor to BeiGene Switzerland
BEIGENE (06160.HK) received a Shareholding of 12.9016 million ordinary shares from JPMorgan, worth approximately 1.581 billion Hong Kong dollars.
On December 13, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on December 13, JPMorgan (JPMORGANCHASECO) increased its shareholding of BEIGENE (06160.HK) by a total of 12.9016 million shares of common stock at an average on-market price of HK$122.5394 per share and an off-market average price of HK$122.5744 per share on December 9, valued at approximately HK$1.581 billion. After the increase, JPMorgan's latest shareholding is 0.139 billion shares, with the proportion of shares rising from 9.92% to 10.94%. Image source: Stock disclosure from the Stock Exchange.
Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors